| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Is patient travel distance associated with survival on phase II clinical trials in oncology?
|
J Natl Cancer Inst
|
2003
|
3.09
|
|
2
|
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.
|
J Clin Oncol
|
2010
|
1.90
|
|
3
|
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.
|
Cancer
|
2011
|
1.70
|
|
4
|
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease.
|
Clin Cancer Res
|
2008
|
1.68
|
|
5
|
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
|
J Clin Oncol
|
2003
|
1.52
|
|
6
|
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.
|
Clin Cancer Res
|
2004
|
1.44
|
|
7
|
Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation.
|
Head Neck
|
2006
|
1.40
|
|
8
|
Aspiration in chemoradiated patients with head and neck cancer.
|
Arch Otolaryngol Head Neck Surg
|
2007
|
1.39
|
|
9
|
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.38
|
|
10
|
Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review.
|
Int J Radiat Oncol Biol Phys
|
2003
|
1.33
|
|
11
|
Predictors of competing mortality in advanced head and neck cancer.
|
J Clin Oncol
|
2009
|
1.27
|
|
12
|
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
|
J Clin Oncol
|
2008
|
1.23
|
|
13
|
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
|
Clin Cancer Res
|
2007
|
1.19
|
|
14
|
Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers.
|
Int J Oncol
|
2006
|
1.13
|
|
15
|
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.
|
Int J Oncol
|
2004
|
1.09
|
|
16
|
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
|
Head Neck
|
2004
|
1.08
|
|
17
|
Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer.
|
Head Neck
|
2007
|
1.05
|
|
18
|
Chemoradiation for patients with advanced oral cavity cancer.
|
Laryngoscope
|
2010
|
1.04
|
|
19
|
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
|
Head Neck
|
2010
|
0.99
|
|
20
|
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
|
Cancer Invest
|
2007
|
0.96
|
|
21
|
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
|
Cancer
|
2011
|
0.95
|
|
22
|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
|
J Thorac Oncol
|
2008
|
0.95
|
|
23
|
Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review.
|
Cancer Treat Rev
|
2003
|
0.92
|
|
24
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
|
Clin Cancer Res
|
2004
|
0.92
|
|
25
|
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.
|
Am J Clin Oncol
|
2011
|
0.92
|
|
26
|
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy.
|
Head Neck
|
2009
|
0.92
|
|
27
|
Free-flap reconstruction in the doubly irradiated patient population.
|
Plast Reconstr Surg
|
2008
|
0.91
|
|
28
|
Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.
|
Arch Otolaryngol Head Neck Surg
|
2008
|
0.91
|
|
29
|
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.
|
J Thorac Oncol
|
2012
|
0.91
|
|
30
|
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
|
Oncologist
|
2003
|
0.90
|
|
31
|
Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.90
|
|
32
|
Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study.
|
Lung Cancer
|
2002
|
0.89
|
|
33
|
Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer.
|
Arch Otolaryngol Head Neck Surg
|
2009
|
0.87
|
|
34
|
Chemoreirradiation for recurrent salivary gland malignancies.
|
Radiother Oncol
|
2010
|
0.86
|
|
35
|
Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer.
|
Arch Otolaryngol Head Neck Surg
|
2010
|
0.83
|
|
36
|
Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer.
|
Radiother Oncol
|
2010
|
0.83
|
|
37
|
Planned post-chemoradiation neck dissection: significance of radiation dose.
|
Laryngoscope
|
2006
|
0.83
|
|
38
|
Chemoradiation for patients with large-volume laryngeal cancers.
|
Head Neck
|
2011
|
0.83
|
|
39
|
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.
|
Head Neck Oncol
|
2011
|
0.83
|
|
40
|
Lymph node density--prognostic value in head and neck cancer.
|
Head Neck
|
2013
|
0.82
|
|
41
|
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
|
Clin Cancer Res
|
2003
|
0.82
|
|
42
|
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
|
Int J Oncol
|
2006
|
0.81
|
|
43
|
Reirradiation: a potentially curative approach to locally or regionally recurrent head and neck cancer.
|
Curr Opin Oncol
|
2002
|
0.80
|
|
44
|
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.80
|
|
45
|
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy.
|
Oral Oncol
|
2012
|
0.79
|
|
46
|
Reirradiation of recurrent head and neck cancers with curative intent.
|
Semin Oncol
|
2004
|
0.78
|
|
47
|
Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.
|
Cancer J
|
2005
|
0.78
|
|
48
|
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
|
J Thorac Oncol
|
2008
|
0.78
|
|
49
|
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
|
J Clin Oncol
|
2006
|
0.78
|
|
50
|
Radiation-induced leiomyosarcoma: does antimetabolite chemotherapy contribute? A report of three cases.
|
Sarcoma
|
2003
|
0.77
|
|
51
|
Reply to s. Chakraborty et al.
|
J Clin Oncol
|
2015
|
0.75
|
|
52
|
Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers.
|
Am J Clin Oncol
|
2007
|
0.75
|